Breast Cancer Screenings May Reveal Heart Disease Risk

Every year, roughly 40 million women in the United States sit for a mammogram — an X-ray designed to catch breast cancer early. But a convergence of new research now suggests those same images may carry a second, equally critical signal: the risk of heart attack, stroke, and cardiovascular death. And with artificial intelligence entering the picture, the era of the dual-purpose mammogram may be closer than anyone expected.

The Accidental Discovery Hiding in Plain Sight

For decades, radiologists have noticed white specks lining the breast arteries on mammographic images — a finding called breast arterial calcification, or BAC. These calcium deposits in the walls of breast arteries are markers of vascular aging and arterial stiffness, the same underlying process that drives coronary artery disease. But because the mammogram's job was to find tumors, not heart disease, these incidental findings were largely ignored [1].

That is now changing. A cascade of major studies published in late 2025 and early 2026 has established a clear, graded relationship between the severity of breast arterial calcification and the likelihood of serious cardiovascular events — and the medical community is paying attention.

The Numbers Behind the Connection

The evidence arrives from multiple directions, each reinforcing the same conclusion.

A landmark study published in the European Heart Journal in March 2026, led by Dr. Hari Trivedi at Emory University, analyzed mammograms from 123,762 women with no known cardiovascular disease. Using an AI model trained on images and health records from over 56,000 patients at Emory Healthcare, the researchers found a stark, dose-response relationship between calcification severity and cardiovascular risk [2][3]:

• Women with mild breast arterial calcification were roughly 30% more likely to experience a major cardiovascular event than women with no calcification.
• Those with moderate calcification faced a risk more than 70% higher.
• Women with severe calcification had two to three times the risk of serious heart disease, stroke, or cardiovascular death.

Critically, these associations held even in women under 50 — a population typically considered low-risk for heart disease — and persisted after researchers accounted for traditional risk factors like diabetes, high blood pressure, and smoking [2].

Source: European Heart Journal / Emory University (2026)

Data as of Mar 9, 2026CSV

A separate analysis presented at the American College of Cardiology's Annual Scientific Session found that five-year survival rates diverged sharply by calcification burden: 95.3% of women with the least calcification (under 10 mm²) survived five years, compared to 86.4% of those with the heaviest deposits (over 40 mm²) — representing a nearly threefold difference in mortality risk [4].

Penn State: Tracking Calcification Over Time

While cross-sectional studies had already linked BAC to heart risk, a team at Penn State College of Medicine broke new ground by examining how calcification progresses over time — and what that progression means.

Dr. Matthew Nudy and colleagues analyzed data from 10,348 women who had sequential mammograms, with an average of 4.1 years between scans and 5.6 years of follow-up. Using CureMetrix's cmAngio AI software, they categorized calcification severity into four tiers: negative, mild, moderate, and severe [5][6].

The results, presented at the Radiological Society of North America meeting in December 2025, were striking:

• At baseline, 19.4% of women had detectable breast arterial calcification.
• Women whose calcification progressed from negative to positive on follow-up mammograms had a 41% higher risk of major adverse cardiovascular events and death.
• Those who progressed from mild to a higher category faced a 59% higher risk.
• Women who progressed from moderate to severe had a 93% higher risk — nearly doubling their chances of a serious cardiac event.

Perhaps most alarmingly, the study showed that calcification can worsen in as little as one year, suggesting that serial mammography could serve as a monitoring tool for cardiovascular risk trajectory [5].

Source: Penn State College of Medicine / RSNA 2025

Data as of Dec 3, 2025CSV

A Problem of Staggering Scale

The potential impact of this research must be understood against the backdrop of cardiovascular disease's toll on American women — a toll that is growing.

Heart disease is already the leading cause of death in women, killing roughly one in three each year and claiming more lives than all forms of cancer combined [7]. In 2022, the most recent year with final data, 941,652 Americans died of cardiovascular disease — an increase of more than 10,000 from the previous year [8].

But the projections are even more alarming. According to the American Heart Association's 2026 statistical update, nearly 6 in 10 U.S. women are projected to have some form of cardiovascular disease by 2050. The increase will be especially pronounced among younger women: by 2025, nearly one-third of women aged 22 to 44 are expected to have cardiovascular disease, up from fewer than one in four previously [8][9].

Source: American Heart Association 2026 Statistical Update

Data as of Feb 27, 2026CSV

The racial disparities are equally stark. By 2050, more than 70% of Black women are projected to have high blood pressure, and nearly 28% will have diabetes — both major drivers of cardiovascular events [8]. Yet cardiovascular risk in women remains systematically underdetected: fewer than 40% of women report knowing their cholesterol levels, according to the European Society of Cardiology [2].

Why This Matters: The Screening Gap

This is where the mammogram's dual potential becomes transformative. The United States already has a robust breast cancer screening infrastructure: approximately 79.8% of women aged 50-74 reported having a mammogram within the past two years as of 2023 [10]. That is tens of millions of women already in the imaging pipeline every year.

By contrast, dedicated cardiovascular screening for women is far less systematic. Coronary artery calcium (CAC) scoring — the gold standard for assessing arterial calcification — requires a separate CT scan, carries additional radiation exposure, and costs $100 to $400 out of pocket, as it is often not covered by insurance. Many women, particularly those without symptoms, never receive it.

"Breast arterial calcification is a good predictor for cardiovascular disease, especially in patients younger than age 60," said Dr. Theo Dapamede, a postdoctoral fellow at Emory University and lead author of the ACC study. The finding is significant precisely because it could reach women who would never be referred for a cardiac CT [4].

A Kaiser Permanente study of over 5,000 women aged 60-79, published in Circulation: Cardiovascular Imaging, found that 26% of women in that age group had BAC — and those women were 51% more likely to develop heart disease or stroke and 23% more likely to develop any type of cardiovascular disease compared to women without calcification. The study also found that BAC prevalence exceeded 50% in women aged 75-79 [11].

The AI Revolution: From Incidental to Automated

The critical bottleneck has always been detection. Radiologists reading mammograms are focused on finding cancer, not grading arterial calcification. Asking them to systematically assess and report BAC for every patient would add time, complexity, and cost to an already strained workflow.

Artificial intelligence solves this problem. The AI models developed by the Emory-Mayo Clinic collaboration and by CureMetrix can automatically segment calcified vessels in mammographic images, quantify the calcification burden, and generate a cardiovascular risk score — all without any additional human effort or patient inconvenience [3][5].

The Emory-Mayo model, trained on data from patients who had mammograms between 2013 and 2020 with at least five years of follow-up, performed particularly well in women under 60 and those aged 60 to 80 [4]. Washington Radiology and Solis Mammography have already begun offering "Mammo+Heart" services that include automated BAC assessment alongside standard breast cancer screening [12].

Still, widespread clinical adoption faces hurdles. The Emory-Mayo AI tool has not yet received FDA approval, and researchers emphasize the need for external validation and clinical trials. "The main steps needed are integrating the AI tool into existing imaging workflows and establishing clear guidelines for notifying patients and doctors," Dr. Trivedi told the European Heart Journal. "We are now planning a clinical trial designed to test these steps" [2].

The Diagnostic Sensitivity Question

Not everyone is ready to declare mammographic BAC a cardiovascular screening tool. Some cardiologists note that while the association between BAC and cardiovascular events is statistically robust, the sensitivity and specificity of BAC as a standalone predictor are imperfect.

A meta-analysis published in the American Journal of Roentgenology found that the sensitivity of BAC for detecting coronary artery calcification was 63%, with a specificity of 76% and overall accuracy of 70% [13]. That means roughly one-third of women with coronary calcification would be missed by BAC alone, and about one-quarter of flagged women might have false positives.

Proponents counter that BAC is not intended to replace traditional cardiac risk assessment but to augment it — catching women who fall through the cracks of conventional screening. In this framing, a mammogram-detected BAC finding would trigger further evaluation, not a diagnosis.

Implications for Policy and Practice

If the research holds up in clinical trials, the implications are significant. Incorporating automated BAC assessment into routine mammography could:

• Identify at-risk women earlier, particularly those under 60 who are often overlooked by traditional cardiovascular risk calculators.
• Reduce healthcare costs by leveraging existing imaging infrastructure rather than ordering additional tests.
• Address disparities by reaching women in mammography networks who may lack access to cardiologists or dedicated cardiac screening.
• Enable longitudinal monitoring by tracking calcification progression across serial mammograms.

The U.S. Preventive Services Task Force currently recommends biennial mammography for women aged 40-74 [10]. If BAC reporting were integrated into that recommendation, millions of women could receive cardiovascular risk information they currently lack — at zero additional cost, radiation, or clinic visits.

What Comes Next

The field is moving fast. Dr. Trivedi's team at Emory is planning a prospective clinical trial to test the integration of AI-powered BAC assessment into routine mammography workflows. CureMetrix's cmAngio software is already being evaluated at multiple institutions. And the American Heart Association's recognition of BAC as a "cardiovascular risk enhancer" in its scientific statements signals growing institutional support [11].

For the 40 million American women who get a mammogram each year, the message is clear: the images captured by that machine may hold far more information than anyone previously thought. The question is no longer whether mammograms can detect heart disease risk — it is how quickly the healthcare system can act on what they reveal.